Here are the latest stories being discussed in biopharma today:

Healthcare Market News:

Amylyx Withdraws ALS Drug, Relyvrio Following Trial Failure
Amylyx has announced its decision to withdraw its ALS drug, Relyvrio, from the market following a critical Phase 3 trial failure. The company also plans to lay off approximately 70% of its workforce. The move has been praised by experts as upholding the company’s commitment to doing ‘what’s right for patients’.

New Team at Leash Bio Prioritises More Data for AI
Ex-Recursion members launch Leash Bio, a startup focusing on the importance of data in the AI field. Its significant database and open competition for AI groups mark its distinct approach.

eFFECTOR’s Lead Lung Cancer Program Hits Dead-end, Triggers Stock Crash
eFFECTOR Therapeutics’ lead lung cancer candidate fell through after a failed Phase 2 study. This development caused their stock to plummet by 82%.

Mixed Results for CureVac’s Interim Phase 2 Data for Seasonal Flu Vaccine
CureVac’s interim data from an ongoing Phase 2 trial indicate that their seasonal flu vaccine boosted antibody titers in influenza A strains but failed in influenza B.

Candel’s Phase 2 Data Promising for Pancreatic Cancer; Microbiome Biotech Raises £27M
Candel Therapeutics’ viral immunotherapy demonstrates effective results against pancreatic cancer in a small Phase 2 trial while Microbiome biotech secures £27M funding.

FDA Approval for Basilea’s Antibiotic
Basilea’s antibiotic for severe bacterial infections has been approved by the FDA.

Startups Bag Major Funding
PBM unicorn startup Rightway raised $109M, according to a recent filing. Also, EnteroBiotix secured £27.3M funding to advance its lead candidate through a Phase 2 trial.